Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Docetaxel 80mg/4ml solution for infusion vials
0801050D0AAADAD
|
Docetaxel | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Docetaxel 80mg/8ml solution for infusion vials
0801050D0AAAFAF
|
Docetaxel | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Docusate compound 5ml enema
0106020I0AAAGAG
|
Docusate sodium (Systemic) | Docusate sodium | Gastro-Intestinal System | No data available |
|
Docusol Adult 50mg/5ml oral solution
0106020I0BFAAAI
|
Docusol | Docusate sodium | Gastro-Intestinal System | No data available |
|
Docusol Constipation Relief 50mg/5ml oral solution
0106020I0BFACAI
|
Docusol | Docusate sodium | Gastro-Intestinal System | No data available |
|
Dog rose 750mg capsules
091200000AAFFFF
|
Generic compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Dolasetron 100mg/5ml solution for injection ampoules
0406000Z0AAADAD
|
Dolasetron mesilate | Dolasetron mesilate | Central Nervous System | No data available |
|
Dolasetron 12.5mg/0.625ml solution for injection ampoules
0406000Z0AAACAC
|
Dolasetron mesilate | Dolasetron mesilate | Central Nervous System | No data available |
|
Dolasetron 200mg tablets
0406000Z0AAABAB
|
Dolasetron mesilate | Dolasetron mesilate | Central Nervous System | No data available |
|
Dolasetron 50mg tablets
0406000Z0AAAAAA
|
Dolasetron mesilate | Dolasetron mesilate | Central Nervous System | No data available |
|
Dolenio 1500mg tablets (Actavis)
091200000BFUMDW
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Dolenio 500mg tablets
091200000BFUXDG
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Dolenio 750mg tablets
091200000BFUYDI
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Dolmatil 400mg tablets
0402010U0BBABAQ
|
Dolmatil | Sulpiride | Central Nervous System | No data available |
|
Dolobid 250mg tablets
1001010D0BBAAAA
|
Dolobid | Diflunisal | Musculoskeletal and Joint Diseases | No data available |
|
Dolobid 500mg tablets
1001010D0BBABAB
|
Dolobid | Diflunisal | Musculoskeletal and Joint Diseases | No data available |
|
Dolocodon PR 10mg tablets
0407020ADBIADAF
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 20mg tablets
0407020ADBIAAAG
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 40mg tablets
0407020ADBIABAH
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 5mg tablets
0407020ADBIACAK
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolomite + D tablets
091000000BBFQBU
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
Doloxene 100mg capsules
0407020E0BBAAAA
|
Doloxene | Dextropropoxyphene | Central Nervous System | No data available |
|
Dolutegravir 10mg tablets
0503010AHAAABAB
|
Dolutegravir | Dolutegravir | Infections | No data available |
|
Dolutegravir 25mg tablets
0503010AHAAACAC
|
Dolutegravir | Dolutegravir | Infections | No data available |
|
Dolutegravir 5mg/Abacavir 60mg/Lamivudine 30mg disp tab SF
0503010AZAAAAAA
|
Dolutegravir/Abacavir/Lamivudine | Dolutegravir/Abacavir/Lamivudine | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.